Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Alger Weatherbie Specialized Growth Fund. This analysis is provided for institutional research purposes only and is not investment advice.
"The Alger Weatherbie Specialized Growth Fund underperformed its benchmark in Q3 2025 but remains highly constructive on secular digitization, AI infrastructure, and medical innovation tailwinds."
In Q3 2025, the Alger Weatherbie Specialized Growth Fund (Class A) underperformed the Russell 2500 Growth Index, delivering a 4.11% return (without sales charge) versus the index's 10.73%. Despite the underperformance, U.S. equity markets were broadly constructive, supported by strong second-quarter earnings, moderating inflation, and the Federal Reserve's 25-basis-point rate cut. Semtech, Impinj, and Artivion were the top performance contributors due to robust Q2 earnings and strong guidance. Conversely, SPS Commerce, Palomar Holdings, and Vertex detracted from returns, primarily due to cautious customer spending and lowered full-year revenue outlooks. The managers remain highly constructive on secular opportunities in corporate digitization, cloud computing, and AI infrastructure, further boosted by domestic tax incentives.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
High-conviction positioning: The Alger Weatherbie Specialized Growth Fund underperformed its benchmark in Q3 2025 but remains highly constructive on secular digitization, AI infrastructure, and medical innovat...
Growth Outlook
Market outlook remains above average conviction: The Alger Weatherbie Specialized Growth Fund underperformed its benchmark in Q3 2025 but remains highly constructive on secular digitization, AI infrastructure, and medical innovat...
Risk Appetite
Risk appetite posture is above average conviction: The Alger Weatherbie Specialized Growth Fund underperformed its benchmark in Q3 2025 but remains highly constructive on secular digitization, AI infrastructure, and medical innovat...
Capital Deployment
Manager actively deployed capital into high-conviction opportunities. The Alger Weatherbie Specialized Growth Fund underperformed its benchmark in Q3 2025 but remains highly constructive on secular digitization, AI infrastructure, and medical innovat...
Forward Guidance
Forward guidance signal: The Alger Weatherbie Specialized Growth Fund underperformed its benchmark in Q3 2025 but remains highly constructive on secular digitization, AI infrastructure, and medical innovat...
Language Signal
Tone analysis indicates above average conviction language: The Alger Weatherbie Specialized Growth Fund underperformed its benchmark in Q3 2025 but remains highly constructive on secular digitization, AI infrastructure, and medical innovat...
Perceived Risk
Perceived risk level is evaluated as moderate conviction. The Alger Weatherbie Specialized Growth Fund underperformed its benchmark in Q3 2025 but remains highly constructive on secular digitization, AI infrastructure, and medical innovat...
Opportunity Density
Opportunity density index indicates above average conviction actionable entry points. The Alger Weatherbie Specialized Growth Fund underperformed its benchmark in Q3 2025 but remains highly constructive on secular digitization, AI infrastructure, and medical innovat...
Time Horizon
Investment time horizon reflects a high conviction orientation. The Alger Weatherbie Specialized Growth Fund underperformed its benchmark in Q3 2025 but remains highly constructive on secular digitization, AI infrastructure, and medical innovat...
